Back to Screener

Healthcare

Rapid Therapeutic Science Laboratories, Inc.(RTSL)

Live Price

Offline

$0.0001

+0.00% today

1Y Change

-98.57%

Window

Jun 23, 2025 โ†’ Jun 12, 2026

Market Cap
โ€”
Revenue Growth
0.0%
EPS Growth
0.0%
Dividend Yield
0.0%

Coverage: 245 bars ยท Jun 23, 2025 โ†’ Jun 12, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Rapid Therapeutic Science Laboratories, Inc. (RTSL) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 98.6% across the available one-year price window (Jun 23, 2025 โ†’ Jun 12, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of 0.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS 0.0%, free cash flow 0.0% with operating margin 0.0% and ROIC -23.0%. Stock Foundry combines RTSL price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Sector Context

How this name stacks up against nearby peers on first-pass metrics.

Revenue Growth

Below sector median

0.0% vs +7.6% peer median

Operating Margin

Below sector median

0.0% vs +19.4% peer median

What Changed This Quarter

Latest report context and the signals most likely to have changed the story.

Latest report is on the board

2023 was reported on Jun 30, 2023, but the surprise data is still limited.

The setup is mixed rather than one-directional

Revenue is 0.0% and EPS is 0.0%, while operating margin sits near 0.0%.

Earnings Reaction Memory

How the stock has tended to move after recent reports.

Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.

View quarter-by-quarter reaction table
QuarterEPS ฮ”1D5D20D
2023
Jun 30, 2023
โ€”+0.0%+0.0%+0.0%
2023
Mar 31, 2023
โ€”+0.0%+0.0%+0.0%
2022
Dec 31, 2022
โ€”+0.0%+0.0%+0.0%

Benchmark Comparison

Normalized Performance vs SPY

Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.

1Y shared range

RTSL

โ€”

Normalized return

SPY

โ€”

S&P 500

Excess Return

โ€”

Relative to SPY

RTSL Max Drawdown

-98.57%

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for RTSL and SPY.

Calendar-year return history is still loading or unavailable.
Rapid Therapeutic Science Laboratories, Inc. logo

Company Overview

Rapid Therapeutic Science Laboratories, Inc.

Other OTC

Dallas, TX, US
Visit rtslco.comCall IR800 497 6059

Rapid Therapeutic Science Laboratories, Inc. operates as a biotech company. The company engages in the aerosol delivery of non-psychoactive cannabinoids to the blood stream for treatment of chronic pain, post-traumatic stress disorder, insomnia, surgery recovery, and other ailments. It offers pressurized meter dose inhaler, a device that delivers a measured amount of aerosolized inhalant in a mist to the lungs; sublingual oral spray devices; and water-soluble cannabidiol and cannabigerol isolates under the nhaler brand. The company was formerly known as Holly Brothers Pictures, Inc. and changed its name to Rapid Therapeutic Science Laboratories, Inc. in January 2020. Rapid Therapeutic Science Laboratories, Inc. was incorporated in 2013 and is based in Dallas, Texas. Rapid Therapeutic Science Laboratories, Inc. was a former subsidiary of Texas Mdi, Inc.

Leadership
Donal R. Schmidt Jr.
IPO Date
Jun 14, 2017
Employees
3
Street Address
5580 Peterson Lane
Mailing
Dallas, TX, 75201
Region
Dallas, TX, US
Reporting Currency
USD
Investor Line
800 497 6059
Last Updated
May 4, 2026
CIK: 0001575659ISIN: US7534312043CUSIP: 753431105
Reports in USDSEC Registered

Key Fundamentals

Valuation, growth, profitability, and balance sheet signals.

Valuation

P/E
โ€”
EV/EBITDA
โ€”
Price/Sales
โ€”
Price/Book
โ€”

Growth

Revenue
0.0%
EPS
0.0%
Free Cash Flow
0.0%

Profitability

Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
5.9%
ROIC
-23.0%

Balance Sheet

Debt/Equity
โ€”
Current Ratio
0.04

Earnings Reports

๐Ÿ“… Last reportedJun 30, 2023
PeriodB/MEPSEPS ฮ”RevenueRev ฮ”
โ€”
Jun 30, 23
0.01
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Mar 31, 23
0.07
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Dec 31, 22
0.00
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Sep 30, 22
-0.07
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Jun 30, 22
-0.10
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Mar 31, 22
-0.30
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Dec 31, 21
-0.16
Est โ€”
โ€”
60M
Est โ€”
โ€”
โ€”
Sep 30, 21
-0.08
Est โ€”
โ€”
50M
Est โ€”
โ€”
โ€”
Jun 30, 21
-0.07
Est โ€”
โ€”
424M
Est โ€”
โ€”
โ€”
Mar 31, 21
-0.07
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Sep 30, 20
-0.10
Est โ€”
โ€”
1.6B
Est โ€”
โ€”
โ€”
Jun 30, 20
-0.09
Est โ€”
โ€”
129.3B
Est โ€”
โ€”
โ€”
Mar 31, 20
-0.00
Est โ€”
โ€”
9.1B
Est โ€”
โ€”
โ€”
Dec 31, 19
-0.06
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Sep 30, 19
-1.41
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Jun 30, 19
-1.43
Est โ€”
โ€”
โ€”
Est โ€”
โ€”

Latest News

No news articles available

Official Releases

Company announcements and filings-style updates.

Official
No official releases available

Next Step

Keep the research moving

After the overview, the strongest next step is usually chart context or a tighter compare set.

Explore the advanced chart guideRead how to compare stocks